CryoPort (NASDAQ:CYRX) Price Target Raised to $17.00

Key Points

• BTIG Research raised CryoPort's price target to $17.00 (from $15.00) and keeps a "buy" rating, implying roughly a 66.5% upside; the MarketBeat consensus remains a "Moderate Buy" with an average target of $14.79.
• CryoPort's latest quarter slightly missed EPS (-$0.21 vs. -$0.19) but beat revenue estimates ($45.45M vs. $42.92M); the stock trades near $10.21 with a market cap of about $512.5M and a PE of 7.73.
• Insiders, including the CEO, sold shares in mid‑March (about 59,939 shares worth ~$471K over three months), while institutional ownership is very high at 92.9%, with large additions from firms like UBS and Millennium.

CryoPort (NASDAQ:CYRX - Get Free Report) had its price objective upped by BTIG Research from $15.00 to $17.00 in a research note issued to investors on Tuesday, MarketBeat reports. The firm presently has a "buy" rating on the stock. BTIG Research's price target indicates a potential upside of 66.50% from the company's previous close.

A number of other research analysts have also issued reports on the stock. Weiss Ratings reiterated a "sell (d+)" rating on shares of CryoPort in a research note on Friday, March 27th. Craig Hallum started coverage on shares of CryoPort in a research note on Monday, March 30th. They set a "buy" rating and a $15.00 price target on the stock. Needham & Company LLC boosted their price target on shares of CryoPort from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, Wall Street Zen lowered shares of CryoPort from a "hold" rating to a "sell" rating in a research note on Sunday. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $14.79.

CryoPort Stock Performance

NASDAQ CYRX opened at $10.21 on Tuesday. The firm has a market cap of $512.52 million, a PE ratio of 7.73 and a beta of 1.75. CryoPort has a one year low of $5.31 and a one year high of $11.45. The firm's fifty day moving average is $8.92 and its two-hundred day moving average is $9.32.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. The business had revenue of $45.45 million during the quarter, compared to analyst estimates of $42.92 million. Research analysts predict that CryoPort will post -0.73 earnings per share for the current year.

Insiders Place Their Bets

In other CryoPort news, insider Mark W. Sawicki sold 3,235 shares of the company's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total transaction of $25,880.00. Following the transaction, the insider directly owned 103,697 shares in the company, valued at approximately $829,576. This represents a 3.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jerrell Shelton sold 7,918 shares of the company's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $63,344.00. Following the transaction, the chief executive officer owned 1,054,501 shares in the company, valued at $8,436,008. The trade was a 0.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 59,939 shares of company stock worth $471,183. 10.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CYRX. Mak Capital One LLC acquired a new position in CryoPort during the third quarter worth about $7,756,000. UBS Group AG grew its position in shares of CryoPort by 112.7% in the third quarter. UBS Group AG now owns 1,331,521 shares of the company's stock valued at $12,623,000 after purchasing an additional 705,649 shares during the last quarter. Millennium Management LLC grew its position in shares of CryoPort by 23.8% in the fourth quarter. Millennium Management LLC now owns 3,244,802 shares of the company's stock valued at $31,150,000 after purchasing an additional 623,896 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its position in shares of CryoPort by 283.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company's stock valued at $4,970,000 after purchasing an additional 387,440 shares during the last quarter. Finally, First Eagle Investment Management LLC acquired a new stake in shares of CryoPort in the fourth quarter valued at approximately $2,996,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

CryoPort Company Profile

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.